What XenTech does

XenTech SAS is a French preclinical oncology Contract Research Organization (CRO) founded in 2006 as a spin-off of Institut Curie, headquartered in Évry-Courcouronnes on the Genopole biopark. The company specializes in Patient-Derived Xenograft (PDX) models — patient tumor samples grafted into immunodeficient mice and maintained by serial transplantation — used for preclinical cancer drug efficacy evaluation, biomarker discovery, and resistance-mechanism research. XenTech's scientists published the world's first PDX proof of concept at Institut Curie in 1989, and the company has built a catalog of 200+ PDX models across solid tumors (60+ in breast cancer including 43 TNBC, 9 ER+, 5 HER2+, 3 Luminal B), 50+ PDX-derived in vitro cell lines, and a proprietary multi-omic molecular database (gene sequences, mutations, expression, CNV, miRNA, protein markers). Two differentiated sub-offerings anchor the platform: the MATCH-R collection of acquired-resistance PDX models co-developed with Gustave Roussy (NCT02517892, 600-patient trial), and access to 400+ pediatric PDX models via the ITCC-P4 European IMI2 consortium.

The business model is fee-for-service B2B preclinical CRO work, delivered through a team of Study Directors led by Marie Tavernier and a business development function (Vincent Verbiest) targeting pharmaceutical and biotechnology companies, academic research institutions, and pediatric oncology programs. Services span in vivo studies (drug efficacy, PK/PD tolerability, Mouse Clinical Trials, biomarker discovery, immuno-oncology) executed in an ISO 9001-accredited vivarium (CERFE) and in vitro pre-screening using PDX-derived cell lines, with customer access supported by a self-serve database portal (app.xentech.eu). Go-to-market is event-driven and science-led, with sustained annual presence at AACR, EORTC-NCI-AACR, EACR, World ADC, PARP & DDR Inhibitors Summit, BIOPHARM-US, and BIO-EUROPE. Strategic academic and institutional partners include Institut Curie, Gustave Roussy, VHIO, VUMC, Oregon Health & Science University, Manchester University, and AP-HP; Urosphere operates as a sister company offering complementary organoid capability, and a 2026 joint AACR booth formalizes the integrated organoid-plus-PDX positioning. Public funding support has been received from BPIFRANCE, IMI, and ANR, and the company holds ISO 9001 certification through its vivarium partner CERFE. Revenue is not publicly disclosed.

Name

XenTech

Legal name

XenTech SAS

Website

https://xentech.eu

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

XenTech is a French preclinical oncology CRO (spin-off of Institut Curie, founded 2006) providing Patient-Derived Xenograft (PDX) models, Mouse Clinical Trials, and molecular database services to pharmaceutical, biotechnology, and academic clients globally.

Ownership category

akta.pro rank

Product category

Preclinical Oncology Contract Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Preclinical oncology research
• Patient-derived xenografts
• Cancer drug evaluation
• Immuno-oncology models
• Contract research services

Headquarters

HQ city

Évry

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Preclinical Contract Research Services: Fee-for-service contracts providing preclinical oncology research services to pharmaceutical companies, biotech firms, and academic institutions. Services include in vivo PDX studies, in vitro screening, biomarker discovery, and Mouse Clinical Trials.
2. Model Access and Testing Services: Access to preclinical models (PDX, PDX-derived cells) for drug testing. Part of ITCC-P4 consortium providing models to pharma and academics for pediatric oncology drug testing.
3. Partnership and Collaboration Services: Biomarker research projects through partnership or collaborations from early stage to already-in-clinic programs. Includes fee-for-service contracts and collaborative research arrangements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

XenTech is a preclinical Contract Research Organization (CRO) that provides oncology drug efficacy evaluation services built around Patient-Derived Xenograft (PDX) tumor models in immunodeficient mice, complemented by in vitro screening, Mouse Clinical Trials, biomarker discovery, and a proprietary molecular database. The company serves pharmaceutical companies, biotechnology firms, and academic institutions globally, delivering study design through dedicated Study Directors and a business development team. Its portfolio includes specialized breast cancer, pediatric, and acquired-resistance (MATCH-R) model panels.

Product overview

XenTech is a preclinical CRO specializing in oncology research, offering an integrated platform centered on Patient-Derived Xenograft (PDX) models as its core technology. The company provides a comprehensive portfolio including PDX models (its foundational gold-standard offering), Human CDX, Immuno-Oncology models, and PDX-Derived In Vitro Cell Lines. Services span In Vivo studies (drug efficacy, PK/PD, Mouse Clinical Trials, biomarker discovery) and In Vitro studies (screening, flow cytometry). The proprietary Molecular Database supports model selection. Notable sub-offerings include the MATCH-R collection of resistant models and specialized Breast Cancer and Pediatric PDX panels. All services are backed by over 35 years of expertise originating from Institut Curie.

Differentiator

Problem solved

Functional benefit

Brands

• MATCH-R: A growing collection of PDX models established from patients who demonstrated acquired resistance to last generation therapies (newly approved or in clinical evaluation drugs). These models are used to explore mechanisms of acquired resistance and support design of more effective therapies.
• MATCH-R Collection

Products and services

• PDX (Patient-Derived Xenografts) Patient-derived tumor xenograft models established from surgical samples grafted subcutaneously into immunodeficient mice and maintained by serial transplantation. Considered the gold standard for preclinical oncology drug evaluation and biomarker discovery. Includes 200+ PDX models across breast, colorectal, lung, pancreatic, and other cancer types, with full molecular characterization available.
• Human CDX (Cell Line-Derived Xenografts) Cell line-derived xenograft models provided upon request using reference cell lines from ATCC for preclinical oncology studies.
• Immuno-Oncology Models
• PDX-Derived In Vitro Cell Lines (PDXDC)
• MATCH-R Collection
• In Vivo Studies
• In Vitro Studies
• Molecular Database
• Mouse Clinical Trials (MCT)
• Breast Cancer PDX Panel World's premiere breast cancer PDX panel including 60+ fully characterized models: 43 TNBC, 9 ER+, 5 HER2+, 3 Luminal B (ER+ HER2+) models, including princeps models from Institut Curie. Among the most representative and recognized worldwide, intended as XenTech's breast cancer reference offering.
• Pediatric PDX Models (ITCC-P4)

Quantifiable outcome

• Over 2500 in vivo studies completed with industrial and academic partners
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Institut CuriecoreStrategic or Co-development PartnerXenTech is a spin-off of Institut Curie, France's largest cancer research institute. Princeps breast cancer PDX models originated from Institut Curie. Ongoing research collaborations and key partnership for model development. XenTech scientists have published reference articles since 1989.
• Gustave RoussycoreStrategic or Co-development PartnerStrategic partnership for MATCH-R precision medicine trial (NCT02517892). PDX models established from patients with acquired resistance to targeted therapies. Gilles Vassal from Gustave Roussy forms interim management of ITCC-P4 gGmbH. 300 patients' biopsies used to generate resistance PDX models.
• ITCC-P4 (Innovative Therapies for Children with Cancer)coreStrategic or Co-development PartnerPublic-private partnership funded by European IMI2. XenTech is one of three biotech companies (with Charles River Laboratories and EPO-Berlin-Buch) offering preclinical testing with pediatric tumor models. Project developed 400 patient-specific pediatric tumor models. ITCC-P4 gGmbH is non-profit company providing model access.
• GenopoleminorOthersXenTech website is hosted by Genopole. Company is located in Genopole campus, France's leading biopark dedicated to biotechnology and genomics research with 60+ biotech companies.
• UrospherecoreStrategic or Co-development PartnerSister company fully dedicated to preclinical oncology research. Joint presence at AACR Annual Meeting 2026 (Booth #5036) reflecting strong complementarity in model types and expertise for integrated preclinical solution from organoids to PDX models.
• VHIO (Vall d'Hebron Institute of Oncology)minorStrategic or Co-development PartnerAcademic research collaboration in cancer research.
• VUMC (Vanderbilt University Medical Center)minorStrategic or Co-development PartnerAcademic research collaboration in cancer research.
• Oregon Health & Science UniversityminorStrategic or Co-development PartnerAcademic research collaboration in cancer research.
• Manchester UniversityminorStrategic or Co-development PartnerAcademic research collaboration in cancer research.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Large diversified CRO with a significant preclinical oncology and PDX model offering. Sits alongside XenTech as one of three biotech/CRO operators within the ITCC-P4 consortium, providing a direct benchmark for how a global incumbent competes in the same academic and pharma-funded niche.
• WuXi AppTec: Largest global CRO with preclinical oncology capabilities, including PDX and in vivo pharmacology services. Relevant as a benchmark for scale economics and as an alternative vendor for sponsors evaluating PDX study providers.
• Labcorp Early Development / Covance: Diversified CRO with preclinical and translational oncology offerings serving large pharma sponsors. Comparable in the broader sense that it includes PDX-style in vivo efficacy work as part of a much wider preclinical-to-clinical service portfolio.

Direct peers

• Crown Bioscience: Specialized preclinical oncology CRO with extensive PDX collections across multiple indications and a global vivarium footprint. Directly comparable to XenTech in the pharma-sponsored PDX/Mouse Clinical Trial value proposition and similarly focused on translational oncology.
• Champions Oncology: Public (CSBR) oncology-focused CRO with a core PDX platform ( TumorGraft ) comparable in technology to XenTech. Competes head-to-head for pharma and biotech sponsors seeking PDX efficacy, biomarker discovery, and translational preclinical services.
• EPO-Berlin-Buch: German preclinical CRO co-equal to XenTech as the third ITCC-P4 consortium operator and offering parallel in vivo oncology pharmacology services. Provides a directly comparable specialized, EU-based competitor with similar scientific profile and customer base.
• Urosphere: Sister company fully dedicated to preclinical oncology research with a complementary organoid platform. Joint booth presence with XenTech at AACR 2026 (Booth #5036) reflects identical target customers and overlapping scientific offering, making them a tightly coupled peer and bundled-sales counterpart.
• Oncodesign: French preclinical CRO with a strong oncology and pharmacology service portfolio and similar geographic/conference footprint. Competes with XenTech for the same France-based biotech and pharma sponsors and shares a European clinical-translational value proposition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Xentech_PDX
• LinkedInlinkedin.com/company/xentech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XenTech